Changes to TB care in an outpatient centre during the COVID-19 pandemic

A New Quantum Dot-Based Lateral Flow Immunoassay for the Rapid Detection of Influenza Viruses

Rapid and accurate diagnosis of influenza is crucial to contain influenza virus outbreaks. In clinical settings, lateral flow immunoassays (LFIAs) are widely used for rapid influenza antigen detection. The choice of label plays an important role in determining the sensitivity of the LFIA. Quantum dots are one of the most promising fluorescent reporters. Here, we evaluated a novel quantum dot-based assay, QuantumPACK Easy Influenza A + B (QuantumPACK Easy; BioSquare Inc., Korea). A total of 394 nasopharyngeal swab samples, including 94 influenza A virus-positive, 98 influenza B virus-positive, 175 influenza A and B virus-negative, and 27 other respiratory pathogen-positive samples, were collected. Samples were tested with QuantumPACK Easy, Allplex RP real-time RT-PCR assay (Allplex RP; Seegene, Korea), and Sofia Influenza A + B FIA (Sofia; Quidel, CA, USA). The sensitivity and specificity of QuantumPACK Easy was analyzed using the Allplex RP assay. The agreement between QuantumPACK Easy and Sofia assays was also analyzed. The sensitivity of QuantumPACK Easy for influenza A and B was 80.9% and 83.7%, respectively. The specificity of QuantumPACK Easy was 100%. Cross-reactivity with other respiratory pathogens was not observed. Total agreement between QuantumPACK Easy and Sofia was 89.6% (kappa 0.783). The sensitivity of the Sofia assay was 66.0% for influenza A virus and 61.2% for influenza B virus. QuantumPACK Easy had acceptable performance, with better sensitivity than a commercially available antigen detection assay, possibly due to the characteristics of the quantum dot.

Evidence of TB Services at Primary Healthcare Level during COVID-19: A Scoping Review

Tuberculosis (TB) is still a major public health concern, despite the availability of preventative and curative therapies. Significant progress has been made in the past decade towards its control. However, the emergence of the novel coronavirus disease 2019 (COVID-19) has disrupted numerous essential health services, including those for TB. This scoping review maps the available evidence on TB services at the primary healthcare (PHC) level during the COVID-19 period. A comprehensive literature search was conducted in PubMed, Web of Science, Medline OVID, Medline EBSCO, and Scopus. A total of 820 articles were retrieved from the databases and 21 met the eligibility criteria and were used for data extraction. The emerging themes were the effect of the COVID-19 pandemic on TB services, patient and provider experiences, recommendations for TB services during the COVID-19 period, and the implementation of the recommendations. The review found that the mitigation strategies, as well as fear and stigma experienced at the start of the COVID-19 pandemic may have led to TB cases potentially going undetected, which may threaten TB treatment outcomes. Therefore, efforts must be directed at finding these missing cases and ensuring that PHC facilities are equipped to adequately diagnose and treat them.

Different disease, same challenges: Social determinants of tuberculosis and COVID-19

Infectious diseases, such as tuberculosis (TB) and the novel coronavirus (COVID-19) relate to environmental factors, understanding of which is essential to inform policy and practice and tackle them effectively. The review follows the conceptual framework offered by the World Health Organization Commission on Social Determinants of Health (defined as "all those material, psychological and behavioural circumstances linked to health and generically indicated as risk factors' in the conventional epidemiological language"). It describes the social factors behind TB and COVID-19, the commonalities between the two diseases, and what can be learned so far from the published best practices. The social determinants sustaining TB and COVID-19 underline the importance of prioritising health and allocating adequate financial and human resources to achieve universal health coverage and health-related social protection while addressing the needs of vulnerable populations. Rapid and effective measures against poverty and other major social determinants and sources of inequality are urgently needed to develop better health in the post-COVID-19 world.